Gilead Sciences' (GILD) Overweight Rating Reaffirmed at Barclays PLC

Andrew Cummings
October 13, 2017

Company shares are trading at $82.57 which is marginally higher than the 50 day moving average which is $81.81 and which is quite a bit higher than the 200 day moving average of $72.01. About shares traded. Gilead Sciences, Inc. It has underperformed by 59.71% the S&P500. West Oak Capital LLC raised its holdings in shares of Gilead Sciences by 0.7% in the second quarter. West Oak Capital LLC lifted its holdings in shares of Gilead Sciences by 0.7% during the 2nd quarter. Westover Capital Advisors LLC now owns 5,563 shares of the biopharmaceutical company's stock worth $378,000 after acquiring an additional 46 shares during the last quarter.

Traders bought shares of Gilead Sciences, Inc. The stock decreased 0.03% or $0.01 during the last trading session, reaching $28.98. The Ohio-based Cincinnati Specialty Underwriters Ins has invested 2.71% in Gilead Sciences, Inc.

In recent action, Gilead Sciences, Inc. It has underperformed by 38.50% the S&P500. They expect $0.47 EPS, up 461.54% or $0.60 from last year's $-0.13 per share. MYL's profit will be $646.23M for 7.98 P/E if the $1.20 EPS becomes a reality. After $0.46 actual EPS reported by Centurylink Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.


Wesbanco Bank Inc increased Continental Resources (NYSE:CLR) stake by 16,375 shares to 132,764 valued at $4.29 million in 2017Q2. Capstone Asset Management owns 223,599 shares.

Among 19 analysts covering Centurylink Inc. Atlanta Grp holds 0.1% in Gilead Sciences, Inc. Equities analysts predict that Gilead Sciences will post $8.75 EPS for the current fiscal year. The firm has "Hold" rating by Jefferies given on Wednesday, August 31. Cantor Fitzgerald maintained Mylan N.V. (NASDAQ:MYL) on Wednesday, August 9 with "Hold" rating. Robert W. Baird reiterated an outperform rating and set a $87.00 price target on shares of Gilead Sciences in a research report on Thursday, July 13th. The rating was maintained by KeyBanc Capital Markets with "Hold" on Monday, September 11. The company was maintained on Wednesday, May 31 by Mizuho. The stock has "Hold" rating by RBC Capital Markets on Sunday, September 17. On Tuesday, November 8 the stock rating was upgraded by Oppenheimer to "Outperform".

Investors sentiment decreased to 1.08 in 2017 Q2. Its the same as in 2017Q1. The company has market cap of $312.75 million. (NASDAQ:GILD). 6.11M are held by Ubs Asset Americas. Marathon Asset Management Llp holds 858,982 shares. Glenmede Tru Co Na has 29,536 shares for 0% of their portfolio. Price T Rowe Assoc Md invested in 0% or 89,545 shares. It also increased its holding in Apple Inc (NASDAQ:AAPL) by 850,681 shares in the quarter, for a total of 851,567 shares, and has risen its stake in Ishares Tr (TLT). Schlumberger Ltd (NYSE:SLB) was raised too. Therefore 60% are positive. U.S. Silica had 71 analyst reports since July 30, 2015 according to SRatingsIntel. BidaskClub raised shares of Gilead Sciences from a "strong sell" rating to a "sell" rating in a report on Thursday, June 22nd. (NASDAQ:GILD) earned "Outperform" rating by Leerink Swann on Friday, February 5. Hilltop Inc owns 0.06% invested in Gilead Sciences, Inc. (NASDAQ:GILD) earned "Overweight" rating by Piper Jaffray on Thursday, November 5. Standpoint Research has "Buy" rating and $110 target. Credit Suisse maintained it with "Outperform" rating and $95 target in Wednesday, September 14 report. Cowen & Co maintained the stock with "Buy" rating in Tuesday, July 25 report. (NASDAQ:GILD) rating on Thursday, October 5. The rating was initiated by Cowen & Co on Tuesday, October 13 with "Market Perform". The company was downgraded on Friday, July 29 by Argus Research. The company was maintained on Wednesday, March 23 by Credit Suisse. Alton Gregg H also sold $325,114 worth of Gilead Sciences, Inc. The value in dollars went from $6,557,000 to $7,227,000 a change of $670,000 for the reporting period. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.11 by $0.45. SLCA's profit will be $39.25 million for 15.86 P/E if the $0.47 EPS becomes a reality. After $2.91 actual earnings per share reported by CIGNA Corporation for the previous quarter, Wall Street now forecasts -19.59% negative EPS growth.


Since May 1, 2017, it had 0 insider buys, and 5 insider sales for $11.13 million activity.

Investors of record on Friday, September 15th were issued a dividend of $0.52 per share. Its down 0.30, from 2.5 in 2017Q1. 0 funds opened positions while 3 raised stakes. Manufacturers Life Ins The reported 7,950 shares or 0% of all its holdings. The Massachusetts-based Ballentine Ptnrs Ltd Liability Corporation has invested 0.05% in Gilead Sciences, Inc. Princeton Portfolio Strategies Group LLC now owns 9,766 shares of the biopharmaceutical company's stock worth $691,000 after buying an additional 41 shares during the last quarter. (NASDAQ:CEVA) to report earnings on November, 1. Finally, Westover Capital Advisors LLC lifted its holdings in shares of Gilead Sciences by 0.8% during the 1st quarter. (NASDAQ:GILD) or 73,333 shares.

Sns Financial Group Llc decreased Us Bancorp Del (NYSE:USB) stake by 6,279 shares to 82,168 valued at $4.27M in 2017Q2. Ibm Retirement Fund reported 0.21% of its portfolio in CIGNA Corporation (NYSE:CI). Blair William And Il stated it has 1.51M shares. Axa owns 0% invested in Centurylink Inc (NYSE:CTL) for 26,034 shares.


Other reports by iNewsToday

FOLLOW OUR NEWSPAPER